Gilead Sciences has agreed to pay $202 million to resolve allegations that it used speaker programs to provide kickbacks to doctors, encouraging them to prescribe its HIV medications. The U.S. Attorney’s Office in Manhattan stated that from 2011 to 2017, Gilead offered improper incentives—including $23.7 million in speaker fees, meals, and travel—to induce doctors to prescribe drugs like Biktarvy, Complera, Descovy, Genvoya, Odefsey, and Stribild. These actions led to fraudulent claims submitted to Medicare and Medicaid. The case originated from a 2016 whistleblower lawsuit filed by Dr. Paul Bellman under the False Claims Act. Gilead chose to settle to avoid the cost and distraction of potential litigation and had already allocated funds for the settlement.
The settlement requires Gilead to pay nearly $177 million to the federal government and the remainder to various states. Despite the legal issues, Gilead's HIV drug sales reached $19.61 billion in 2024, marking an 8% annual increase. The company said, “Gilead’s HIV speaker programs have served to educate healthcare professionals about the appropriate use and benefits of these important medicines. These efforts are important for healthcare providers and patients to have the necessary information to make the best decisions for their care. Gilead’s therapies have transformed the treatment paradigm for HIV, and Gilead will continue to drive innovation to meet patients’ needs.”
